Ilaria Dal Pra

Prof. Ilaria Dal Pra

Dept. surgery, dentistry, Pediatrics and gynecology
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VBVittorina Della Bianca
Vittorina Della Bianca
SDStefano Dusi
Stefano Dusi
EBErcolina Bianchini
Ercolina Bianchini
IPIlaria Pierpaola Dal Prà
Ilaria Pierpaola Dal Prà
FRFilippo Rossi
Filippo Rossi
The deposition of β-amyloid in the brain is the key pathogenetic event in Alzheimer’s disease. Among the various mechanisms proposed to explain the neurotoxicity of β-amyloid deposits, a new one, recently identified in our and other laboratories, suggests that β-amyloid is indirectly neurotoxic by activating microglia to produce toxic inflammatory mediators such as cytokines, nitric oxide, and oxygen free radicals. Three findings presented here support this mechanism, showing that β-amyloid peptides (25-35), (1-39), and (1-42) activated the classical NADPH oxidase in rat primary culture of microglial cells and human phagocytes: 1) The exposure of the cells to β-amyloid peptides stimulates the production of reactive oxygen intermediates; 2) the stimulation is associated with the assembly of the cytosolic components of NADPH oxidase on the plasma membrane, the process that corresponds to the activation of the enzyme; 3) neutrophils and monocytes of chronic granulomatous disease patients do not respond to β-amyloid peptides with the stimulation of reactive oxygen intermediate production. Data are also presented that the activation of NADPH oxidase requires that β-amyloid peptides be in fibrillary state, is inhibited by inhibitors of tyrosine kinases or phosphatidylinositol 3-kinase and by dibutyryl cyclic AMP, and is potentiated by interferon-γ or tumor necrosis factor-α.

1 May 2005 in Biomaterials
Verified
Journal Article
Closed access
IPIlaria Pierpaola Dal Prà
Ilaria Pierpaola Dal Prà
GFGiuliano Freddi
Giuliano Freddi
JMJasminka Minic
Jasminka Minic
ACAnna Chiarini
Anna Chiarini
UAUbaldo Armato
Ubaldo Armato

1 December 2019 in Burns & Trauma
Verified
Journal Article
Open access
PDF file
PHPeng Hu
Peng Hu
QYQinxin Yang
Qinxin Yang
QWQi Wang
Qi Wang
CSChenshuo Shi
Chenshuo Shi
DWDali Wang
Dali Wang
ACAnna Chiarini
Anna Chiarini
Abstact: Cutaneous regeneration at the wound site involves several intricate and dynamic processes which require a series of coordinated interactions implicating various cell types, growth factors, extracellular matrix (ECM), nerves, and blood vessels. Mesenchymal stromal cells (MSCs) take part in all the skin wound healing stages playing active and beneficial roles in animal models and humans. Exosomes, which are among the key products MSCs release, mimic the effects of parental MSCs. They can shuttle various effector proteins, messenger RNA (mRNA) and microRNAs (miRNAs) to modulate the activity of recipient cells, playing important roles in wound healing. Moreover, using exosomes avoids many risks associated with cell transplantation. Therefore, as a novel type of cell-free therapy, MSC-exosome -mediated administration may be safer and more efficient than whole cell. In this review, we provide a comprehensive understanding of the latest studies and observations on the role of MSC-exosome therapy in wound healing and cutaneous regeneration. In addition, we address the hypothesis of MSCs microenvironment extracellular vesicles (MSCs-MEVs) or MSCs microenvironment exosomes (MSCs-MExos) that need to take stock of and solved urgently in the related research about MSC-exosomes therapeutic applications. This review can inspire investigators to explore new research directions of MSC-exosome therapy in cutaneous repair and regeneration.

1 April 2002 in Journal of Experimental Medicine
Verified
Journal Article
Open access
GPGiovanni Perini
Giovanni Perini
VDVittorina Della-Bianca
Vittorina Della-Bianca
VPValeria Politi
Valeria Politi
GVGiuliano Della Valle
Giuliano Della Valle
IPIlaria Pierpaola Dal Prà
Ilaria Pierpaola Dal Prà
UAUbaldo Armato
Ubaldo Armato
The neurodegenerative changes in Alzheimer's disease (AD) are elicited by the accumulation of β-amyloid peptides (Aβ), which damage neurons either directly by interacting with components of the cell surface to trigger cell death signaling or indirectly by activating astrocytes and microglia to produce inflammatory mediators. It has been recently proposed that the p75 neurotrophin receptor (p75NTR) is responsible for neuronal damage by interacting with Aβ. By using neuroblastoma cell clones lacking the expression of all neurotrophin receptors or engineered to express full-length or various truncated forms of p75NTR, we could show that p75NTR is involved in the direct signaling of cell death by Aβ via the function of its death domain. This signaling leads to the activation of caspases-8 and -3, the production of reactive oxygen intermediates and the induction of an oxidative stress. We also found that the direct and indirect (inflammatory) mechanisms of neuronal damage by Aβ could act synergistically. In fact, TNF-α and IL-1β, cytokines produced by Aβ-activated microglia, could potentiate the neurotoxic action of Aβ mediated by p75NTR signaling. Together, our results indicate that neurons expressing p75NTR, mostly if expressing also proinflammatory cytokine receptors, might be preferential targets of the cytotoxic action of Aβ in AD.

20 April 2017 in Frontiers in Neuroscience
Verified
Journal Article
Open access
ACAnna Chiarini
Anna Chiarini
UAUbaldo Armato
Ubaldo Armato
EGEmanuela Gardenal
Emanuela Gardenal
LGLi Gui
Li Gui
IPIlaria Pierpaola Dal Prà
Ilaria Pierpaola Dal Prà
The two main drivers of Alzheimer’s disease (AD), amyloid-β (Aβ) and hyperphosphorylated Tau (p-Tau) oligomers cooperatively accelerate AD progression, but a hot debate is still ongoing about which of the two appears first. Here we present preliminary evidence showing that Tau and p-Tau are expressed by untransformed cortical adult human astrocytes in culture and that exposure to such cells to an Aβ42 proxy, Aβ25-35, which binds the calcium-sensing receptor (CaSR) and activates its signaling, significantly increases intracellular p-Tau levels, an effect CaSR antagonist (calcilytic) NPS 2143 wholly hinders. The astrocytes also release both Tau and p-Tau by means of exosomes into the extracellular medium, an activity that could mediate p-Tau diffusion within the brain. Preliminary data also indicate that exosomal levels of p-Tau increase after Aβ25-35 exposure, but remain unchanged in cells pre-treated for 30-min with NPS 2143 before adding Aβ25-35. Thus our previous and present findings raise the unifying prospect that AβCaSR signaling plays a crucial role in AD development and progression by simultaneously activating (i) the amyloidogenic processing of amyloid precursor holoprotein, whose upshot is a surplus production and secretion of Aβ42 oligomers, and (ii) the GSK-3β-mediated increased production of p-Tau oligomers which are next released extracellularly inside exosomes. Therefore, as calcilytics suppress both effects on Aβ42 and p-Tau metabolic handling, these highly selective antagonists of pathological AβCaSR signaling would effectively halt AD’s progressive spread preserving patients’ cognition and life quality.

Verified
Journal Article
Open access
PDF file
ACAnna Chiarini
Anna Chiarini
Ubaldo ArmatoUbaldo Armato
Ubaldo Armato
PHPeng Hu
Peng Hu
IPIlaria Pierpaola Dal Prà
Ilaria Pierpaola Dal Prà
Fibrillar aggregates and soluble oligomers of both Amyloid-β peptides (Aβs) and hyperphosphorylated Tau proteins (p-Tau-es), as well as a chronic neuroinflammation are the main drivers causing progressive neuronal losses and dementia in Alzheimer’s disease (AD). However, the underlying pathogenetic mechanisms are still much disputed. Several endogenous neurotoxic ligands, including Aβs, and/or p-Tau-es activate innate immunity-related danger-sensing/pattern recognition receptors (PPRs) thereby advancing AD’s neuroinflammation and progression. The major PRR families involved include scavenger, Toll-like, NOD-like, AIM2-like, RIG-like, and CLEC-2 receptors, plus the calcium-sensing receptor (CaSR). This quite intricate picture stresses the need to identify the pathogenetically topmost Aβ-activated PRR, whose signaling would trigger AD’s three main drivers and their intra-brain spread. In theory, the candidate might belong to any PRR family. However, results of preclinical studies using in vitro nontumorigenic human cortical neurons and astrocytes and in vivo AD-model animals have started converging on the CaSR as the pathogenetically upmost PRR candidate. In fact, the CaSR binds both Ca2+ and Aβs and promotes the spread of both Ca2+ dyshomeostasis and AD’s three main drivers, causing a progressive neurons’ death. Since CaSR’s negative allosteric modulators block all these effects, CaSR’s candidacy for topmost pathogenetic PRR has assumed a growing therapeutic potential worth clinical testing.